The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin after progression on conventional irinotecan-containing chemotherapy for metastatic pancreatic adenocarcinoma.
 
Kyunghye Bang
No Relationships to Disclose
 
Jaekyung Cheon
No Relationships to Disclose
 
Jae Ho Jeong
No Relationships to Disclose
 
Hyeon-Su Im
No Relationships to Disclose
 
Kyu-Pyo Kim
No Relationships to Disclose
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Changhoon Yoo
Stock and Other Ownership Interests - Oncocross
Honoraria - Bayer; Ipsen; SERVIER
Consulting or Advisory Role - LSK BioPharma
Speakers' Bureau - Bayer; Celgene; Eisai; Ipsen; Merck Sharp & Dohme
Research Funding - AstraZeneca; Bayer; CKD pharm; SERVIER